Recently, an increasing consideration has been given to the oncogenic HER2 activation in CRC where its over-expression has been reported in 2% considering CRC overall, increasing up to 5% in stage III and IV KRAS exon 2 wild-type tumors [97,98,99]. Here, ERBB2 is linked to colorectal carcinoma.